Eligibility for Treatment of Hepatitis C Virus Infection among Young Injection Drug Users in 3 US Cities | Zendy

Holly Hagan | Zendy; Mary H. Latka | Zendy; James Campbell | Zendy; Elizabeth T. Golub | Zendy; Richard S. Garfein | Zendy; D. A. Thomas | Zendy; Farzana Kapadia | Zendy; Steffanie A. Strathdee | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Eligibility for Treatment of Hepatitis C Virus Infection among Young Injection Drug Users in 3 US Cities

Author(s) -

Holly Hagan,

Mary H. Latka,

James Campbell,

Elizabeth T. Golub,

Richard S. Garfein,

D. A. Thomas,

Farzana Kapadia,

Steffanie A. Strathdee

Publication year - 2006

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/499951

Subject(s) - medicine , hepatitis c virus , drug , depression (economics) , injection drug use , hepatitis c , hepatitis a virus , drug treatment , drug injection , virus , virology , intensive care medicine , immunology , psychiatry , economics , macroeconomics

Among 404 injection drug users aged 18-35 who tested positive for hepatitis C virus (HCV) RNA, 96% had conditions that are potentially unwarranted contraindications for HCV treatment (e.g., problem drinking, moderate-to-severe depression, and recent drug injection). Restrictive eligibility criteria may deny treatment to a large proportion of patients who could benefit from it.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research